Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing Agricultural University, Nanjing 210095, China.
Vet Microbiol. 2013 Mar 23;162(2-4):850-857. doi: 10.1016/j.vetmic.2012.11.002. Epub 2012 Nov 12.
Riemerella anatipestifer (RA) is one of the most important bacterial pathogens of ducks and other avian species worldwide. Current approaches for controlling RA are hindered by the absence of effective vaccines, particularly cross-protective vaccines. In this present study, an immunoproteomics approach was used to identify cross-protective vaccine candidates against RA serotype 1 strain RAf63 and serotype 2 strain RAf153. First, whole-cell and secreted proteins of RAf153 and RAf63 were separated by two-dimensional gel electrophoresis. Then, western blotting of the proteome was performed using duck convalescent serum against RAf153, followed by matrix-assisted laser desorption/ionization time of flight mass spectrometry and peptide mass fingerprinting. Finally, common immunoreactive proteins from RAf153 and RAf63 were identified as cross-protective vaccine candidates, and so these were cloned and expressed recombinantly. The cross-protection abilities of purified recombinant protein vaccines were tested against homologous and heterologous virulent strains in a challenge model that followed vaccination. Six proteins were identified as cross-protective vaccine candidates. Three of these proteins showed reactivity with convalescent sera after prokaryotic expression, and the recombinant outer membrane protein A (OmpA) showed high protective indices against challenges with RAf153 (60%) and RAf63 (50%). In summary, we have developed a high-throughout, accurate, rapid and efficient method for the successful selection of cross-protective vaccine candidates.
鸭疫里默氏杆菌(RA)是世界范围内鸭和其他禽类最重要的细菌性病原之一。目前控制 RA 的方法受到缺乏有效疫苗的限制,特别是缺乏交叉保护疫苗。在本研究中,采用免疫蛋白质组学方法鉴定了针对 RA 血清型 1 株 RAf63 和血清型 2 株 RAf153 的交叉保护疫苗候选物。首先,通过二维凝胶电泳分离 RAf153 和 RAf63 的全细胞和分泌蛋白。然后,用鸭康复血清对 RAf153 进行蛋白质组western 印迹,然后进行基质辅助激光解吸/电离飞行时间质谱和肽质量指纹图谱分析。最后,从 RAf153 和 RAf63 中鉴定出共同的免疫反应性蛋白作为交叉保护疫苗候选物,并进行了克隆和重组表达。在随后的接种疫苗挑战模型中,测试了纯化重组蛋白疫苗对同源和异源毒力株的交叉保护能力。鉴定出 6 种蛋白作为交叉保护疫苗候选物。其中 3 种蛋白在原核表达后表现出与康复血清的反应性,重组外膜蛋白 A(OmpA)对 RAf153(60%)和 RAf63(50%)的挑战具有高保护指数。总之,我们已经开发出一种高通量、准确、快速和有效的方法来成功选择交叉保护疫苗候选物。